Re-induction with certolizumab pegol following disease exacerbation during maintenance therapy is effective to regain response and remission

被引：0
|
作者：
Lichtenstein, Gary R.
Mitchev, Krassimir
D'Haens, Geert
机构：
来源：
GASTROENTEROLOGY | 2008年 / 134卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A488 / A488
页数：1
相关论文
共 50 条
  • [1] Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohn's Disease
    Stein, Adam C.
    Rubin, David T.
    Hanauer, Stephen B.
    Cohen, Russell D.
    [J]. INFLAMMATORY BOWEL DISEASES, 2014, 20 (10) : 1722 - 1728
  • [2] Efficacy of Certolizumab Pegol Induction and Maintenance Therapy in Patients With Crohn's Disease Not in Remission Following Active or Placebo Induction
    Sandborn, William J.
    Younes, Ziad H.
    Pierre-Louis, Bosny
    D'Haens, Geert R.
    [J]. GASTROENTEROLOGY, 2012, 142 (05) : S565 - S565
  • [3] Acute exacerbation of rheumatoid interstitial lung disease during the maintenance therapy with certolizumab pegol
    Migita, Kiyoshi
    Tsuji, Yoshika
    Hisatomi, Keiko
    Shigeno, Riyoko
    Izumi, Yasumori
    Iwanaga, Nozomi
    Koga, Tomohiro
    [J]. MODERN RHEUMATOLOGY, 2017, 27 (06) : 1079 - 1082
  • [4] Sustained Remission with No Dose Escalation after Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation: 1-Year Results from PRECiSE 4
    Sandborn, William
    Rubin, David
    Sen, David
    Feagan, Brian
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S439 - S439
  • [5] Long-term maintenance of remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation: 3-year results from the PRECiSE 4 study
    Sandborn, W.
    Schreiber, S.
    Hanauer, S.
    Colombel, J.
    Bloomfield, R.
    Lichtenstein, G.
    [J]. INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S14 - S14
  • [6] Remission Rates in Crohn's Disease Patients Treated With a Re-Induction Regimen of Certolizumab Pegol After Experiencing Disease Exacerbation: 7 Year Results From the Precise 4 Study
    Lee, Scott D.
    Schreiber, Stefan
    Schwartz, David A.
    Burakoff, Robert
    Binion, David G.
    Kayhan, Cem
    Kosutic, Gordana
    Ambarkhane, Sumeet
    Sen, David
    Hasan, Iram
    Spearman, Marshall
    Sandborn, William
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S261 - S261
  • [7] Long-term Maintenance of Remission with No Dose Escalation Aft er Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation: 3-year Results from the PRECiSE 4 Study
    Sandborn, William
    Schreiber, Stefan
    Hanauer, Stephen
    Colombel, Jean-Frederick
    Bloomfield, Ralph
    Lichtenstein, Gary
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S448 - S448
  • [8] RE-induction and maintenance therapy with subcutaneous certolizumab pegial in patients with Crohn's disease following treatment failure: Precise 4 results
    Sandborn, William J.
    Hanauer, Stephen B.
    Rutgeerts, Paul J.
    Colombel, Jean-frederic
    Schreiber, Stefan
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A505 - A505
  • [9] Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
    Vande Casteele, N.
    Feagan, B. G.
    Vermeire, S.
    Yassine, M.
    Coarse, J.
    Kosutic, G.
    Sandborn, W. J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (02) : 229 - 237
  • [10] Long-term Maintenance of Remission with No Dose Escalation After Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation Who Were Naive to Anti-TNF Treatment: 4-Year Results from the PRECiSE 4 Study
    Sandborn, William
    Schreiber, Stefan
    Hanauer, Stephen
    Colombel, Jean-Frederic
    Bloomfield, Ralph
    Lichtenstein, Gary
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S418 - S418
12345